IBA RECEIVES FDA APPROVAL FOR ITS PROTON THERAPY SPECIFIC CONE BEAM CT (CBCT) SOLUTION

IBA has received combined clearances from the U.S. FDA for its imaging platform adaPT Insight and Compact Gantry Beam Line, allowing us to market-launch our Proton Therapy specific Cone Beam Computed Tomography (CBCT) solution in our two PT solutions, Proteus®PLUS and Proteus®ONE (2014 and 2015, respectively).

IBA’s CBCT solution opens the way to increased proton therapy accuracy. As a component of IBA’s Image Guided Proton Therapy (IGPT) solution, CBCT provides 3D imaging for increased accuracy in patient treatment. It is fully integrated with IBA’s imaging platform adaPT Insight, to offer fast 6D corrections of patient positioning for IBA’s Proteus®PLUS and Proteus®ONE. IBA’s first CBCT is at the validation phase and the first clinical use is expected for the second half of 2014.

Learn more HERE